Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — Shareholder Meeting (November 2016)
22 slides from Monash Ivf's shareholder meeting presentation, Nov 24, 2016
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 24 November 2016
Slide 2: Disclaimer
Disclaimer For personal use only The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The info
Slide 3: Chairman's address
For personal use only Chairman’s address Richard Davis 3 Monash IVF Group | Annual General Meeting 2016
Slide 4: Key Achievements
Key Achievements Continued focus on developing industry leading For personal use only science Strong financial result in FY16 Increased market share Diversification through women's imaging expansion KL Fertility in Malaysia continues growth trajectory Science & research investment is pay
Slide 5: Thank you
Thank you For personal use only • Board of Directors • James Thiedeman and senior management team • Our passionate doctors, nurses, scientists and support staff providing superior patient care • Shareholders for continued support 5 Monash IVF Group | Annual General Meeting 2016
Slide 6: CEO Presentation
CEO Presentation For personal use only James Thiedeman 6 Monash IVF Group | Annual General Meeting 2016
Slide 7: Overview of Monash IVF Group
Overview of Monash IVF Group For personal use only Core Assisted Diagnostic and Ancillary Ultrasound Reproductive Services Services 22 clinics 2 specialised 17 clinics laboratories in Victoria 5 service centres and South Australia 18 Sonologists 89 Fertility Specialists 2 Australian st
Slide 8: Track record of strong financial performance
Track record of strong financial performance For personal use only Number of Patient Treatments¹ Revenue ($m) 156.6 17,901 114.0 125.0 14,287 15,861 12,582 96.3 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 3 Year CAGR3 of 12.5% 3 Year CAGR3 of 17.6% EBITDA ($m)2 NPAT ($m)2 49.6 28.8 34.9 38.8 38.8 22.6 2
Slide 9: FY2016 Full Year Highlights
FY2016 Full Year Highlights For personal use only Revenue NPAT EBITDA $156.6m $28.8m $49.6m FY15 $125.0m FY15 $21.4m FY15 $38.8m Up 25.3% on pcp Up 34.6% on pcp Up 27.6% on pcp Cash Conversion1 Total FY16 Dividend Basic EPS 99.1% 8.5c 12.2c FY15 103.3% FY15 6.95 cents FY15 9.2 cents Down 4.1% on pcp
Slide 10: Revenue Analysis
Revenue Analysis Revenue FY16 vs FY15 ($m) For personal use only 160 155 0.6 2.2 150 145 18.3 140 135 1.3 3.4 156.6 130 5.8 125 120 125.0 115 110 FY15 Market growth (ARS) Market share (ARS) Price (ARS) Acquisitions International (ARS) Other FY16 Market growth: $5.8m or 4.6% increase against pcp du
Slide 11: Australian market share - IVF
Australian market share - IVF MVF IVF Patient Treatment Market Share For personal use only % Market share - IVF FY16 FY15 change Key Markets Australia Number of Monash Group IVF Patient Treatments1 in 14,580 13,579 7.4% Monash Group’s Key Markets2 39.7% 23.8% Monash Group market share in Monash Grou
Slide 12: Expanding domestic footprint
Expanding domestic footprint For personal use only Sydney Ultrasound For Women network (11 practices across Sydney, acquired June 2015). Integration with Monash Ultrasound for Women in advanced stages Acquisitions, New Monash IVF (Bondi Junction, Sydney) (acquired December 2014) rebranding to Mo
Slide 13: International – KL Fertility
International – KL Fertility Continued strong growth in volumes achieved by new Fertility For personal use only Specialists in the face of a challenging local economic climate Slight EBITDA margin compression as these specialists gain traction and the GST introduction was felt Building clinic
Slide 14: Sydney Ultrasound for Women (SUFW)
Sydney Ultrasound for Women (SUFW) For personal use only Annual Revenue of $17.7m growing the Group revenues by 13.6% Delivered an EBITDA(1)(2) contribution of $4.0m with an EBITDA margin of 22.8% Group Ultrasound Scan volumes increased by 230.5% vs pcp Increased scale of specialist operatio
Slide 15: Clinicians, Science & Innovation
Clinicians, Science & Innovation For personal use only We have a 40-year history of leadership in scientific excellence and clinical innovation We have great depth of experience in our doctors and clinical teams We established group doctor committees in FY16 to enhance medical and commercial e
Slide 16: Our Brands and Marketing
Our Brands and Marketing For personal use only Market leading positions Local targeted marketing Launching in house non- invasive prenatal testing capability 16 Monash IVF Group | Annual General Meeting 2016 Overview FY2016 Highlights Strategy HIFY2017 Outlook
Slide 17: Strategy FY17 and beyond
Strategy FY17 and beyond Our strategy remains consistent and focused, to profitably grow our business through For personal use only leveraging our scientific capabilities across the clinic network Science, Continue to develop industry leading science and technology technology Deliver patients cl
Slide 18: H1FY2017 Outlook
H1FY2017 Outlook For personal use only Monash IVF Group is well positioned to continue to Subject to trading in the remaining months, we grow its future revenues and earnings as a result of: anticipate reported NPAT for H1FY17 will be • Strong underlying demand fundamentals for IVF and approximately
Slide 19: FY2017 Trading Update
FY2017 Trading Update Patient Treatment Growth Rates in Key 12.0% Markets For personal use only Australian IVF Market softened in Q1FY17 10.4% against very strong comparative volumes in the 10.0% pcp 8.0% Total Key Market1 Patient Treatments increased by 1.0% in 8.0% 7.6% Q1FY17 vs pcp (increased
Slide 20: FY2017 Trading Update - Continued
FY2017 Trading Update - Continued For personal use only Operational & Scientific Update To complement our women’s imaging services, our investment to in house Non Invasive Prenatal Testing was commissioned in November 2016. This ensures we maintain leading edge science and capture the full margin
Slide 21: Summary
Summary Track record of strong long term financial performance For personal use only Delivered a strong performance in FY16 with revenue growth (25.3%) and NPAT growth (34.6%) Acquisitions providing earnings growth in FY16 FY16 results impacted by a strong lift in industry growth rates Fun
Slide 22: Annual General Meeting
For personal use only Annual General Meeting 24 November 2016
Monash IVF Group — Shareholder Meeting (November 2016) on 6ix